Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 2—February 2020
CME ACTIVITY - Research

Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015–2018

Nilay McLaren, Adriana Lopez, Sarah Kidd, John X. Zhang, W. Allan Nix, Ruth Link-Gelles, Adria Lee, and Janell A. RouthComments to Author 
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Cite This Article

Introduction

CME Logo

Medscape CME ACTIVITY

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: January 15, 2020; Expiration date: January 15, 2021

Learning Objectives

Upon completion of this activity, participants will be able to:

•     Compare the clinical and laboratory characteristics of AFM cases reported in the United States during peak vs nonpeak years from 2015 through 2018

•     Compare the clinical and laboratory characteristics of AFM cases reported in the United States during peak years 2016 vs 2018

•     Describe the clinical and public health significance of differences in the clinical and laboratory characteristics of AFM cases reported in the United States during peak vs nonpeak years from 2015 through 2018

CME Editor

Kristina B. Clark, PhD, Copyeditor, Emerging Infectious Diseases. Disclosure: Kristina B. Clark, PhD, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Authors

Disclosures: Nilay McLaren; Adriana Lopez, MHS; Sarah Kidd, MD, MPH; John X. Zhang, PhD; W. Allan Nix, BS; Ruth Link-Gelles, PhD, MPH; Adria Lee, MSPH; and Janell A. Routh, MD, MHS, have disclosed no relevant financial relationships.

Top

Abstract

Observed peaks of acute flaccid myelitis (AFM) cases have occurred biennially since 2014 in the United States. We aimed to determine if AFM etiology differed between peak and nonpeak years, considering that clinical features of AFM differ by virus etiology. We compared clinical and laboratory characteristics of AFM cases that occurred during peak (2016 and 2018, n = 366) and nonpeak (2015 and 2017, n = 50) years. AFM patients in peak years were younger (5.2 years) than those in nonpeak years (8.3 years). A higher percentage of patients in peak years than nonpeak years had pleocytosis (86% vs. 60%), upper extremity involvement (33% vs. 16%), and an illness preceding limb weakness (90% vs. 62%) and were positive for enterovirus or rhinovirus RNA (38% vs. 16%). Enterovirus D68 infection was associated with AFM only in peak years. Our findings suggest AFM etiology differs between peak and nonpeak years.

Acute flaccid myelitis (AFM) is a clinical syndrome characterized by the acute onset of flaccid limb weakness accompanied by spinal cord gray matter lesions. AFM is a known complication of infection with certain viruses, including polioviruses, nonpolio enteroviruses, flaviviruses, herpesviruses, and adenoviruses (17). In the early 1950s, outbreaks of poliovirus caused >15,000 cases of paralysis each year in the United States, but after the introduction of poliovirus vaccines and the elimination of poliovirus in the United States, AFM caused by poliovirus became much less common (8). However, sporadic, poliovirus-negative cases continued to occur (9).

In August 2014, an unusual cluster of AFM in children was identified in Colorado (10). National surveillance was initiated in 2015 and subsequently led to the identification of heightened activity in 2016 and 2018; during these years, peak illness onset occurred during August–October. In contrast, in 2015 and 2017, the number of AFM cases remained low and did not vary by season (11). National experts agree that the AFM epidemiology observed in 2014 is new; this alternating pattern of high activity one year and low activity the next, referred to herein as peak and nonpeak years, with high activity typically in the late summer or early fall, has not been documented before 2014 (1214) (M. Cortese, Centers for Disease Control and Prevention [CDC], Atlanta, GA, USA, pers. comm., 2017 Sep 27). This change suggests the emergence (beginning in 2014) of either a new cause of AFM or a known cause of AFM with a new epidemiologic pattern.

Determining the cause or causes of the biennial increases in AFM cases has implications for the development of treatment and prevention strategies. However, pathogen-specific laboratory testing has yielded limited insight into the underlying cause of this new epidemiology. Different viruses known to be associated with AFM development have been shown to produce distinctive sets of clinical features (15,16). If a single pathogen is responsible for most AFM cases in peak years, cases of illness onset in these years probably would have clinical manifestations distinct from those of illness onset in nonpeak years, when the etiology of cases is likely more mixed. We compared demographic, clinical, and laboratory characteristics of AFM cases in peak versus nonpeak years to evaluate this hypothesis.

Methods

Reporting and Classification

Beginning in August 2014, CDC received reports of patients meeting the clinical criterion for AFM (i.e., acute onset of flaccid limb weakness) through local and state health departments. A panel of expert neurologists classified these patients according to the standardized case definition published by the Council of State and Territorial Epidemiologists in 2015 (17). We defined a confirmed case as an illness in a patient who met the clinical criterion and had magnetic resonance imaging (MRI) showing a spinal cord lesion largely restricted to the gray matter and spanning >1 spinal segment. Our analysis includes only confirmed AFM cases in patients <22 years of age and is limited to 4 complete years of AFM surveillance (January 1, 2015–December 31, 2018).

Laboratory Testing

CDC staff requested sterile site (e.g., blood, serum, and cerebrospinal fluid [CSF]) and nonsterile site (e.g., respiratory and fecal) specimens from each patient and tested these specimens using algorithms described previously (18,19). With specimens from 2015 and 2016, and starting in September 2018 with all received specimens, CDC staff tested for enterovirus/rhinovirus RNA using a 5′ nontranslated region–targeted pan-Enterovirus real-time reverse transcription PCR assay (genus-level detection) and typed those that were positive. For specimens collected during January 2017–August 2018, only the specimens that had tested positive for enterovirus/rhinovirus RNA at an outside institution were requested by CDC staff for testing and typing. In our analysis, we report only the results from CDC laboratory testing.

Data Analysis

To assess trends in AFM activity over time, we assigned patients with confirmed cases to an epidemiologic week according to their date of onset of limb weakness. We compared cases of patients having AFM onset in peak years (i.e., 2016 and 2018) with those of patients having AFM onset in nonpeak years (i.e., 2015 and 2017) and compared cases between the 2 peak years (2016 vs. 2018). We analyzed the demographics, clinical characteristics, and laboratory results of AFM patients that had been systematically collected across all 4 years of surveillance. We defined AFM cases as severe if they included all 3 of the following clinical characteristics: respiratory distress requiring mechanical ventilation to manage, symptomatic cranial nerve involvement, and paralysis of all 4 limbs. We defined CSF pleocytosis as a leukocyte count of >5 cells/mm3.

We entered data into a Microsoft Access (for 2015–2017 data; https://www.microsoft.com) or REDCap (for 2018 data; https://www.project-redcap.org) database and performed descriptive analyses using R Studio version 3.4.1 (https://rstudio.com). Denominators varied slightly by variable because of missing data. We assessed differences in categorical variables using Fisher exact test and compared medians using the Kruskal-Wallis test. We considered p values <0.05 statistically significant.

CDC staff determined that we collected data through the standardized public health surveillance system and not through research involving humans. Thus, this study did not require institutional review board clearance.

Results

Figure

Thumbnail of Confirmed AFM cases in patients &lt;22 years of age by week of limb weakness onset, United States, January 2015–December 2018. AFM, acute flaccid myelitis.

Figure. Confirmed AFM cases in patients <22 years of age by week of limb weakness onset, United States, January 2015–December 2018. AFM, acute flaccid myelitis.

Of 750 suspected AFM cases reported to the CDC during 2015–2018, a total of 416 (n = 18 in 2015, n = 143 in 2016, n = 32 in 2017, and n = 223 in 2018) occurred in patients <22 years of age and were classified as confirmed. Cases in patients of this age group represented 95% of all confirmed cases. The median age of patients with confirmed cases was 5.4 (range 0.3–21.9, interquartile range 3.2–8.7) years; 60% were male. In peak years (2016 and 2018), the increase in confirmed AFM cases started in August, and for both peak years, most patients with confirmed cases had illness onset during August–October (Figure).

When comparing the characteristics of confirmed AFM cases from peak years (2016 and 2018) and nonpeak years (2015 and 2017), we found that patient median age was significantly lower in peak years (5.2 [range 0.4–21.9] years of age) than nonpeak years (8.3 [range 0.3–20.2] years of age; p = 0.02) (Table 1). The limbs affected by AFM also varied; during peak years, a higher percentage of cases involved upper extremity weakness only (33% vs. 16%; p = 0.01) and a lower percentage involved lower extremity weakness only (13% vs. 32%; p<0.001). During peak years, fewer cases could be classified as severe (2% vs. 18%; p<0.001). The percentage of AFM patients who had a preceding illness (i.e., any fever or respiratory illness) during the 4 weeks before limb weakness onset was higher in peak years (90%) than nonpeak years (62%; p<0.001), and CSF pleocytosis was more common among AFM patients in peak years (86%) than in nonpeak years (60%; p<0.001). The percentage of patients with a specimen positive for enterovirus/rhinovirus RNA was significantly greater in peak years (38%) than nonpeak years (16%; p = 0.02). During peak years, a greater percentage of enterovirus/rhinovirus-positive specimens was positive for enterovirus D68 (EV-D68) RNA (54% vs. 0%; p = 0.02).

To evaluate whether the characteristics of cases from nonpeak months were masking the characteristics of cases from peak months, which we hypothesized to be associated with a single pathogen, we conducted a sensitivity analysis comparing cases in peak months (August–October) from peak years (2016 and 2018) with cases from all nonpeak months (January–July and November–December of 2016 and 2018, January–December of 2015 and 2017) (Table 2). Most variables remained significant in the sensitivity analysis. However, the difference in median age between peak and nonpeak years was no longer significant. The percentage of cases with pleocytosis remained significantly higher in peak months than nonpeak months (p<0.001), and in this analysis, the median cell count was also significantly higher in cases in peak months (88 cells/mm3) than in cases in nonpeak months (44 cells/mm3; p<0.001). The percentage of cases with a specimen positive for enterovirus or rhinovirus RNA was no longer significantly greater in peak months (38%) than nonpeak months (31%; p = 0.25). The percentage of EV-D68–positive cases was also no longer significantly greater in peak months (58%) than nonpeak months (37%; p = 0.08).

Patients with illness onset in 2018 and illness onset in 2016 were clinically similar to each other (Table 3), with a few notable exceptions. Cranial nerve lesions were less common in AFM patients in 2018 (19%) than in AFM patients in 2016 (37%; p<0.001). More cases in 2016 (6%) than 2018 (0%; p<0.001) were classified as severe AFM. Compared with AFM patients in 2016, more AFM patients in 2018 were reported to have an illness within the 4 weeks preceding the onset of limb weakness: any fever (68% in 2016 vs. 75% in 2018; p<0.001), respiratory illness (76% in 2016 vs. 80% in 2018; p = 0.01), or gastrointestinal illness (26% in 2016 vs. 36% in 2018; p = 0.002). The percentage of confirmed AFM cases positive for enterovirus/rhinovirus RNA was similar in both peak years. Among all enterovirus/rhinovirus-positive specimens, EV-D68–positive specimens were more common in 2016 (71%) than in 2018 (45%; p = 0.02). However, AFM patients in 2018 (17%) were more likely than those in 2016 (6%; p = 0.21) to be positive for EV-A71 because of a geographically limited outbreak of EV-A71 in Colorado.

To determine whether the differences in case characteristics between peak years could be explained by the EV-A71 outbreak, we conducted a subanalysis in which we removed all EV-A71–positive cases. Differences in clinical characteristics between years remained unchanged; however, the percentage of cases positive for EV-D68 was no longer significantly different (75% vs. 55%; p = 0.07) (Table 4).

Discussion

Five years of national AFM surveillance data show a seasonal, alternate-year pattern of AFM activity. The numbers of confirmed cases in peak years (2016 and 2018) was >5 times the numbers of cases in the previous year. Our analysis demonstrates key clinical differences between cases in peak years and nonpeak years. Patients with AFM onset in peak years were younger, more likely to have had fever or respiratory symptoms within the 4 weeks preceding AFM onset, and more likely to have pleocytosis and upper extremity weakness during hospitalization than those with AFM onset in nonpeak years. These clinical characteristics mirror the presentation of AFM described for cases of onset in 2014 (20). Patients with onset in nonpeak years were more severely affected during acute illness than those with onset in peak years. We also found differences between AFM patients with onset in 2016 and AFM patients with onset in 2018, the 2 peak years. Compared with AFM patients with onset in 2016, those with onset in 2018 were less likely to have severe disease or cranial nerve lesions and were more likely to have a preceding illness before AFM onset.

Differences in the clinical presentation of AFM between peak and nonpeak years are suggestive of differences in AFM etiologies between those years. Likewise, the clinical differences between cases occurring during peak and nonpeak years might be indicative of different virus etiologies between peak and nonpeak years. In our analysis, enterovirus positivity among AFM cases was higher in peak years than in nonpeak years, and EV-D68 was detected only in the cases occurring during peak years. Although this difference disappeared in the sensitivity analysis (suggesting that the enteroviruses circulating in peak years varies slightly by month), EV-D68 detections remained exclusive to cases occurring in peak years. AFM case counts also vary slightly by month in different peak years; the escalation in cases began earlier in 2016 than they did in 2018, and the increase in case counts lasted slightly longer in 2018.

In peak years, overall enterovirus positivity among AFM cases was similar, but significant type-specific variations were noted. EV-D68 was detected more frequently in specimens from AFM patients with onset in 2016 and EV-A71 more often in those with onset in 2018. These variations might have contributed to differences in clinical characteristics seen between peak years. However, removal of EV-A71–positive cases did not eliminate the differences in clinical characteristics between peak years, suggesting that the greater number of EV-D68–positive cases in 2016 contributed to the clinical variability. Distinct AFM clinical presentations have been observed for different enterovirus etiologies (15,16). AFM caused by EV-A71 has been associated with myoclonus, ataxia, weakness, and autonomic instability. In an isolated outbreak in Colorado in 2018, AFM cases associated with EV-A71 were clinically distinct from those not associated with EV-A71 (15). Of note, paralytic syndrome caused by poliovirus is classically characterized by lower extremity weakness of an asymmetric distribution and a preceding mild gastrointestinal illness, features less common among AFM cases in peak years (16).

Although multiple viruses are associated with AFM, growing evidence suggests that nonpolio enteroviruses and specifically EV-D68 are linked to the changes in AFM epidemiology that started in 2014 (21,22). Enteroviruses were the most common viruses in nasopharyngeal, oropharyngeal, or fecal specimens from confirmed AFM patients identified by CDC researchers, and EV-D68 was the most frequent enterovirus typed (1820). Unlike most other viruses known to cause AFM, enteroviruses routinely circulate and can cause outbreaks during the late summer and early fall months in the United States in a pattern corresponding with the observed seasonal AFM peaks (23,24). Although the United States does not have active national enterovirus surveillance, the enterovirus cases reported in 2 passive laboratory-based reporting systems (the National Enterovirus Surveillance System and the National Respiratory and Enteric Virus Surveillance System) demonstrate the presence of an annual enterovirus season with variation in the enterovirus types circulating each year (23,25,26). Climate, level of immunity in the host population, and viral fitness probably influence which strains dominate each year (27). If >1 specific type of enterovirus causes AFM, differences in circulating types could account for changes in AFM epidemiology from year to year. EV-D68 might be one such type. Respiratory disease surveillance indicates that EV-D68 appears to have circulated in a biennial pattern since 2014, corresponding with trends in AFM. In 2014, 2016, and 2018, increases in respiratory disease caused by EV-D68 coincided with the increases in AFM (24,2830). Since 2014, the correlation between EV-D68 circulation and AFM incidence has also been documented in Canada, Japan, Europe, and Argentina (3134). Global collaborations for the investigation of AFM cases and ongoing, active enterovirus surveillance will enable a broader and more complete picture of enterovirus circulation patterns and their relationships to AFM in the future.

Sentinel surveillance of other enteroviruses, such as coxsackieviruses A2 and A4, have also demonstrated a biennial periodicity like that observed for EV-D68 (35), although neither of these coxsackieviruses have been implicated in clusters of AFM. Rotavirus has also been shown to have a biennial circulation pattern in the postvaccination era (36). These biennial circulation patterns might be caused by an increase in the number of young, unexposed persons during years of low circulation, which leads to a larger number of susceptible persons acquiring and transmitting the infection in the following year. However, this phenomenon cannot fully explain the periodicity seen with AFM. The median age of AFM patients in peak years (5 years) is higher than the median age of patients with respiratory EV-D68 infections (3 years) (24), possibly indicating that other factors besides viral infection affect the risk for AFM development. Moreover, limited data show that persons across all age groups have robust neutralizing antibody titers against EV-D68 (37), including against both historical and contemporary outbreak strains, implying ongoing exposure and infection across the United States. The development of AFM in a small percentage of patients infected by this ubiquitous virus is likely to depend on other factors. Research into environmental or genetic risk factors for AFM development will provide insight into AFM pathogenesis.

Our findings are subject to limitations. First, differences in types of sterile and nonsterile specimens collected and sent to the CDC during 2015–2018 might have affected comparisons of enterovirus/rhinovirus positivity of cases in different years. However, because all enterovirus/rhinovirus-positive specimens were analyzed for enterovirus type, the percentage of type-specific (e.g., EV-D68 or EV-A71) cases among enterovirus/rhinovirus-positive cases would not have been affected. Second, we considered specimens enterovirus- or rhinovirus-positive only if the CDC laboratory confirmed this finding. Although CDC staff requested specimens for testing and confirmation, they might not have received all of them, thus influencing the results reported here. Last, the reporting of suspected cases to CDC public health staff is inconsistent, despite efforts to increase healthcare provider recognition of AFM. Year-to-year variation in reporting can occur, and more comprehensive reporting by healthcare providers might occur during peak years, when their awareness of this illness is heightened.

The alternate-year pattern in peak AFM activity since 2014 highlights a noteworthy shift in the epidemiology of this syndrome. Differences between AFM cases in peak years and nonpeak years provide additional evidence to support the hypothesis of a unique pathogen or pathogens contributing to this new epidemiology. Multiple lines of evidence support EV-D68 as a leading candidate, although additional research is needed. Frequent detection of EV-A71 in AFM cases in 2018 illustrates that >1 virus can cause outbreaks of AFM, and therefore AFM surveillance should not be restricted to detection of a specific pathogen. Healthcare providers thoroughly documenting clinical findings, including results of complete neurologic examinations, and reporting AFM cases to public health authorities, regardless of the pathogen implicated by test results, have implications for treatment and prevention. National AFM surveillance data can be used to characterize yearly variations in AFM cases (temporally, clinically, and etiologically) and illuminate the pathology of this emerging illness.

Mr. McLaren completed this work during a Student Worksite Experience Program internship in the Viral Vaccine Preventable Diseases Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, in Atlanta, Georgia, USA, as a senior in high school at the Massachusetts Academy of Math and Science at Worcester Polytechnic Institute in Worchester, Massachusetts, USA. His primary research interests are neuroscience and infectious diseases.

Top

Acknowledgment

We thank the staff of state and local health departments, without whom these surveillance data would not have been collected. We thank our laboratory colleagues for providing enterovirus testing and typing data and Mary Ann Hall for her careful reading and editing of this manuscript.

Top

References

  1. Solomon  T, Willison  H. Infectious causes of acute flaccid paralysis. Curr Opin Infect Dis. 2003;16:37581. DOIPubMed
  2. Ong  KC, Wong  KT. Understanding Enterovirus 71 neuropathogenesis and its impact on other neurotropic enteroviruses. Brain Pathol. 2015;25:61424. DOIPubMed
  3. Bitnun  A, Yeh  EA. Acute flaccid paralysis and enteroviral infections. Curr Infect Dis Rep. 2018;20:34. DOIPubMed
  4. Saad  M, Youssef  S, Kirschke  D, Shubair  M, Haddadin  D, Myers  J, et al. Acute flaccid paralysis: the spectrum of a newly recognized complication of West Nile virus infection. J Infect. 2005;51:1207. DOIPubMed
  5. Wang  Y, Yu  CY, Huang  L, Han  YY, Liu  YM, Zhu  J. Acute longitudinal and hemorrhagic myelitis caused by varicella-zoster virus in an immunocompetent adolescent. Neurologist. 2015;19:935. DOIPubMed
  6. Ivanova  OE, Yurashko  OV, Eremeeva  TP, Baikova  OY, Morozova  NS, Lukashev  AN. Adenovirus isolation rates in acute flaccid paralysis patients. J Med Virol. 2012;84:7580. DOIPubMed
  7. Sejvar  JJ, Bode  AV, Marfin  AA, Campbell  GL, Ewing  D, Mazowiecki  M, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11:10217. DOIPubMed
  8. Nathanson  N. Eradication of poliomyelitis in the United States. Rev Infect Dis. 1982;4:94050. DOIPubMed
  9. Nihei  K, Naitoh  H, Ikeda  K. Poliomyelitis-like syndrome following asthmatic attack (Hopkins syndrome). Pediatr Neurol. 1987;3:1668. DOIPubMed
  10. Pastula  DM, Aliabadi  N, Haynes  AK, Messacar  K, Schreiner  T, Maloney  J, et al.; Centers for Disease Control and Prevention (CDC). Acute neurologic illness of unknown etiology in children - Colorado, August-September 2014. MMWR Morb Mortal Wkly Rep. 2014;63:9012.PubMed
  11. Centers for Disease Control and Prevention. AFM cases in U.S. [cited 2018 Nov 8]. https://www.cdc.gov/acute-flaccid-myelitis/cases-in-us.html
  12. Van Haren  K, Ayscue  P, Waubant  E, Clayton  A, Sheriff  H, Yagi  S, et al. Acute flaccid myelitis of unknown etiology in California, 2012-2015. JAMA. 2015;314:266371. DOIPubMed
  13. Messacar  K, Schreiner  TL, Maloney  JA, Wallace  A, Ludke  J, Oberste  MS, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015;385:166271. DOIPubMed
  14. Uprety  P, Curtis  D, Elkan  M, Fink  J, Rajagopalan  R, Zhao  C, et al. Association of enterovirus D68 with acute flaccid myelitis, Philadelphia, Pennsylvania, USA, 2009–2018. Emerg Infect Dis. 2019;25:167682. DOIPubMed
  15. Messacar  K, Spence-Davizon  E, Osborne  C, Press  C, Schreiner  TL, Martin  J, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect Dis. 2019;S1473-3099(19)30632-2. DOIPubMed
  16. Pray  LG. Observations on a poliomyelitis outbreak in North Dakota in 1946; with special consideration of spinal fluid findings. J Lancet. 1947;67:2025.PubMed
  17. Council of State and Territorial Epidemiologists. Revision to the standardized surveillance and case definition for acute flaccid myelitis. 2017 [cited 2018 Nov 8]. https://cdn.ymaws.com/www.cste.org/resource/resmgr/2017PS/2017PSFinal/17-ID-01.pdf
  18. Lopez  A, Lee  A, Guo  A, Konopka-Anstadt  JL, Nisler  A, Rogers  SL, et al. Vital signs: surveillance for acute flaccid myelitis—United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68:60814. DOIPubMed
  19. Ayers  T, Lopez  A, Lee  A, Kambhampati  A, Nix  WA, Henderson  E, et al. Acute flaccid myelitis in the United States: 2015–2017. Pediatrics. 2019;144:e20191619. DOIPubMed
  20. Sejvar  JJ, Lopez  AS, Cortese  MM, Leshem  E, Pastula  DM, Miller  L, et al. Acute flaccid myelitis in the United States, August–December 2014: results of nationwide surveillance. Clin Infect Dis. 2016;63:73745. DOIPubMed
  21. Messacar  K, Asturias  EJ, Hixon  AM, Van Leer-Buter  C, Niesters  HGM, Tyler  KL, et al. Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality. Lancet Infect Dis. 2018;18:e23947. DOIPubMed
  22. Mishra  N, Ng  TFF, Marine  RL, Jain  K, Ng  J, Thakkar  R, et al. Antibodies to enteroviruses in cerebrospinal fluid of patients with acute flaccid myelitis. MBio. 2019;10:e01903-19. DOIPubMed
  23. Khetsuriani  N, Lamonte-Fowlkes  A, Oberst  S, Pallansch  MA; Centers for Disease Control and Prevention. Enterovirus surveillance—United States, 1970-2005. MMWR Surveill Summ. 2006;55:120.PubMed
  24. Midgley  CM, Watson  JT, Nix  WA, Curns  AT, Rogers  SL, Brown  BA, et al.; EV-D68 Working Group. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation. Lancet Respir Med. 2015;3:87987. DOIPubMed
  25. Abedi  GR, Watson  JT, Pham  H, Nix  WA, Oberste  MS, Gerber  SI. Enterovirus and human parechovirus surveillance – United States, 2009-2013. MMWR Morb Mortal Wkly Rep. 2015;64:9403. DOIPubMed
  26. Abedi  GR, Watson  JT, Nix  WA, Oberste  MS, Gerber  SI. Enterovirus and parechovirus surveillance — United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67:5158. DOIPubMed
  27. Pons-Salort  M, Oberste  MS, Pallansch  MA, Abedi  GR, Takahashi  S, Grenfell  BT, et al. The seasonality of nonpolio enteroviruses in the United States: Patterns and drivers. Proc Natl Acad Sci U S A. 2018;115:307883. DOIPubMed
  28. Messacar  K, Robinson  CC, Pretty  K, Yuan  J, Dominguez  SR. Surveillance for enterovirus D68 in colorado children reveals continued circulation. J Clin Virol. 2017;92:3941. DOIPubMed
  29. Naccache  S, Bender  J, Desai  J, Van  T, Meyers  L, Jones  J, et al. Acute flaccid myelitis cases presenting during a spike in respiratory enterovirus D68 circulation: case series from a single pediatric referral center. Open Forum Infect Dis. 2017;4(suppl_1):S3056. DOI
  30. Kujawski  SA, Midgley  CM, Rha  B, Lively  JY, Nix  WA, Curns  AT, et al. Enterovirus D68–associated acute respiratory illness—new vaccine surveillance network, United States, July–October, 2017 and 2018. MMWR Morb Mortal Wkly Rep. 2019;68:27780. DOIPubMed
  31. Skowronski  DM, Chambers  C, Sabaiduc  S, Murti  M, Gustafson  R, Pollock  S, et al. Systematic community- and hospital-based surveillance for enterovirus-D68 in three Canadian provinces, August to December 2014. Euro Surveill. 2015;20:30047. DOIPubMed
  32. Hatayama  K, Goto  S, Yashiro  M, Mori  H, Fujimoto  T, Hanaoka  N, et al. Acute flaccid myelitis associated with enterovirus D68 in a non-epidemic setting. IDCases. 2019;17:e00549. DOIPubMed
  33. Knoester  M, Helfferich  J, Poelman  R, Van Leer-Buter  C, Brouwer  OF, Niesters  HGM; 2016 EV-D68 AFM Working Group. Twenty-nine cases of enterovirus-D68-associated acute flaccid myelitis in Europe 2016: a case series and epidemiologic overview. Pediatr Infect Dis J. 2019;38:1621. DOIPubMed
  34. Ruggieri  V, Paz  MI, Peretti  MG, Rugilo  C, Bologna  R, Freire  C, et al. Enterovirus D68 infection in a cluster of children with acute flaccid myelitis, Buenos Aires, Argentina, 2016. Eur J Paediatr Neurol. 2017;21:88490. DOIPubMed
  35. Pons-Salort  M, Grassly  NC. Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science. 2018;361:8003. DOIPubMed
  36. Hallowell  BD, Parashar  UD, Curns  A, DeGroote  NP, Tate  JE. Trends in the laboratory detection of rotavirus before and after implementation of routine rotavirus vaccination—United States, 2000–2018. MMWR Morb Mortal Wkly Rep. 2019;68:53943. DOIPubMed
  37. Harrison  CJ, Weldon  WC, Pahud  BA, Jackson  MA, Oberste  MS, Selvarangan  R. Neutralizing antibody against enterovirus D68 in children and adults before 2014 outbreak, Kansas City, Missouri, USA. Emerg Infect Dis. 2019;25:5858. DOIPubMed

Top

Figure
Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title:
Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015–2018

CME Questions

1.   You are advising a public health department in the United States regarding prevention and management of acute flaccid myelitis (AFM). According to the study by McLaren and colleagues, which of the following statements about the clinical and laboratory characteristics of AFM cases reported in the United States during peak vs nonpeak years from 2015 through 2018 is correct?

A. Peak years were 2015 and 2016, followed by nonpeak years in 2017 and 2018

B. Cases in peak years were older than in nonpeak years (8.3 years vs 5.2 years; p = 0.02)

C. Cases in peak vs nonpeak years had more cerebrospinal fluid pleocytosis (85% vs 63%; p<0.001)

D. Cases in nonpeak vs peak years had a greater proportion of enterovirus (EV)/rhinovirus (RV)-positive specimens (38% vs 16%; p = 0.02)

2.   According to the study by McLaren and colleagues, which of the following statements about clinical and laboratory characteristics of AFM cases reported in the United States during peak years 2016 and 2018 is correct?

A. Compared with cases with onset in 2018, those in 2016 were more severe and less likely to have cranial nerve lesions

B. In 2016, more cases had an illness in the 4 weeks preceding limb weakness onset than in 2018

C. The proportion of confirmed AFM cases that were positive for EV/RV was significantly higher in 2018 than in 2016

D. Among cases positive for EV/RV, those in 2018 vs 2016 were less likely to be positive for EV-D68 (46% vs 70%; p = 0.03) but more likely to be positive for EV-A71 (18% vs 6%; p = 0.13)

3.   According to the study by McLaren and colleagues, which of the following statements about clinical and public health significance of differences in the clinical and laboratory characteristics of AFM cases reported in Colorado during peak vs nonpeak years from 2015 through 2018 is correct?

A. Differences in clinical and laboratory characteristics of AFM in peak vs nonpeak years suggest differences in viral etiologies, informing treatment and prevention strategies

B. Most evidence supports EV-A71 as the most likely pathogen responsible for the new epidemiology of peak years alternating with nonpeak years

C. AFM surveillance should be restricted to detecting the specific pathogen most likely to be implicated in peak activity

D. Healthcare providers should report only AFM cases positive for EV-D68 to public health authorities

Top

Cite This Article

DOI: 10.3201/eid2602.191453

Original Publication Date: 1/15/2020

Related Links

Table of Contents – Volume 26, Number 2—February 2020

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Janell A. Routh, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-5, Atlanta, GA 30329-4027, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: January 15, 2020
Page updated: January 15, 2020
Page reviewed: January 15, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external